Mydocalm (Tolperisone Hydrochloride)

Tolperisone hydrochloride reduces muscle tone by blocking voltage‑gated sodium channels in peripheral nerves and spinal cord neurons, which dampens the transmission of excitatory impulses. This inhibition of spinal reflex activity leads to decreased involuntary muscle contraction and alleviates associated pain without significant central sedation.

The dosage of Mydocalm is individualized by the prescribing clinician based on the patient’s condition, severity, and response to therapy. The prescriber determines the appropriate strength, frequency, and duration, and adjustments are made according to clinical effectiveness and tolerability.

Safety data for tolperisone hydrochloride in pregnancy and lactation are limited, and the product is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should evaluate each case carefully before prescribing.

To place an order, submit an enquiry on the Mydocalm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other centrally acting muscle relaxants such as baclofen or tizanidine, tolperisone has a lower propensity for sedation because it primarily blocks peripheral sodium channels rather than central GABAergic pathways. However, individual response varies, and choice of therapy should consider efficacy, side‑effect profile, drug interactions and patient comorbidities.

Mydocalm tablets should be stored at ambient temperature below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date indicated on the label.

Mydocalm is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration timing (e.g., with meals) may be adjusted based on tolerability and the prescriber’s instructions.

Although uncommon, serious adverse reactions can include severe hypotension, allergic reactions such as rash, urticaria or anaphylaxis, and hematologic abnormalities like leukopenia or thrombocytopenia. Patients should seek immediate medical attention if they experience symptoms such as sudden dizziness, fainting, swelling, or unexplained bruising.

Mydocalm is contraindicated in individuals with known hypersensitivity to tolperisone hydrochloride or any of the excipients. Caution is advised for patients with severe renal impairment, uncontrolled hypertension, or those concurrently using other central muscle relaxants. Pregnant or breastfeeding women should only use it if the potential benefit outweighs the risk, after professional assessment.